Literature DB >> 25205184

Biological agents in psoriatic arthritis.

Roland Kocijan1, Christian Muschitz, Jürgen Rech.   

Abstract

Anti-tumor necrosis factors (TNFs) are effective drugs for the treatment of psoriatic arthritis (PsA) regarding reduction of pain and inflammation, enthesitis, dactylitis, as well as psoriatic skin and nail disease. Moreover, radiographic progression in PsA is decelerated. The efficacy of anti-TNFs seems to be independent of synthetic disease-modifying anti-rheumatic drugs, suggesting only a minor role of combination therapy in PsA. Anti-TNFs are generally well tolerated in patients with PsA. Adverse events are similar to those reported in patients with rheumatoid arthritis. Ustekinumab, a recently approved IL-12/IL-23-antibody is another promising biological agent in the treatment of PsA.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25205184     DOI： 10.1007/s10354-014-0300-2

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  20 in total

1.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Philip J Mease; Dafna D Gladman; Christopher T Ritchlin; Eric M Ruderman; Serge D Steinfeld; Ernest H S Choy; John T Sharp; Peter A Ory; Renee J Perdok; Mark A Weinberg
Journal:  Arthritis Rheum       Date:  2005-10

Review 2.  Interventions for psoriatic arthritis.

Authors:  G Jones; M Crotty; P Brooks
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 3.  Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.

Authors:  S Fénix-Caballero; E J Alegre-del Rey; R Castaño-Lara; F Puigventós-Latorre; J M Borrero-Rubio; J F López-Vallejo
Journal:  J Clin Pharm Ther       Date:  2013-04-17       Impact factor: 2.512

4.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

Authors:  Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G Krueger; Dafna Gladman; Juan Gomez-Reino; Kim Papp; Julie Zrubek; Surekha Mudivarthy; Michael Mack; Sudha Visvanathan; Anna Beutler
Journal:  Arthritis Rheum       Date:  2009-04

5.  Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment.

Authors:  Sarah Cassell; Arthur Kavanaugh
Journal:  J Immune Based Ther Vaccines       Date:  2005-09-02

Review 6.  Treatment recommendations for psoriatic arthritis.

Authors:  C T Ritchlin; A Kavanaugh; D D Gladman; P J Mease; P Helliwell; W-H Boehncke; K de Vlam; D Fiorentino; O Fitzgerald; A B Gottlieb; N J McHugh; P Nash; A A Qureshi; E R Soriano; W J Taylor
Journal:  Ann Rheum Dis       Date:  2008-10-24       Impact factor: 19.103

7.  Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.

Authors:  Iain B McInnes; Joachim Sieper; Jürgen Braun; Paul Emery; Désirée van der Heijde; John D Isaacs; Georg Dahmen; Jürgen Wollenhaupt; Hendrik Schulze-Koops; Joseph Kogan; Shenglin Ma; Martin M Schumacher; Arthur P Bertolino; Wolfgang Hueber; Paul P Tak
Journal:  Ann Rheum Dis       Date:  2013-01-29       Impact factor: 19.103

8.  Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).

Authors:  P J Mease; P Ory; J T Sharp; C T Ritchlin; F Van den Bosch; F Wellborne; C Birbara; G T D Thomson; R J Perdok; J Medich; R L Wong; D D Gladman
Journal:  Ann Rheum Dis       Date:  2008-08-06       Impact factor: 19.103

9.  Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

Authors:  P J Mease; R Fleischmann; A A Deodhar; J Wollenhaupt; M Khraishi; D Kielar; F Woltering; C Stach; B Hoepken; T Arledge; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-08-13       Impact factor: 19.103

10.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Authors:  Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett
Journal:  Ann Rheum Dis       Date:  2014-03-04       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.